Related references
Note: Only part of the references are listed.SGLT-2 inhibitors and nephroprotection: current evidence and future perspectives
Alexia Piperidou et al.
JOURNAL OF HUMAN HYPERTENSION (2021)
Renal protection: a leading mechanism for cardiovascular benefit in patients treated with SGLT2 inhibitors
Davide Margonato et al.
HEART FAILURE REVIEWS (2021)
Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes
Gerasimos Filippatos et al.
CIRCULATION (2021)
Effects of canagliflozin on hyperkalaemia and serum potassium in people with diabetes and chronic kidney disease: insights from the CREDENCE trial
B L Neuen et al.
EUROPEAN HEART JOURNAL (2021)
Dapagliflozin in HFrEF Patients Treated With Mineralocorticoid Receptor Antagonists An Analysis of DAPA-HF
Li Shen et al.
JACC-HEART FAILURE (2021)
Interplay of Mineralocorticoid Receptor Antagonists and Empagliflozin in Heart Failure
Joao Pedro Ferreira et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2021)
Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of CKD: A Scientific Workshop Sponsored by the National Kidney Foundation in Collaboration With the US Food and Drug Administration and European Medicines Agency
Andrew S. Levey et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2020)
2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD
Francesco Cosentino et al.
EUROPEAN HEART JOURNAL (2020)
2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
John B. Buse et al.
DIABETOLOGIA (2020)
Early Change in Albuminuria with Canagliflozin Predicts Kidney and Cardiovascular Outcomes: A Post Hoc Analysis from the CREDENCE Trial
Megumi Oshima et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2020)
Dapagliflozin in Patients with Chronic Kidney Disease
Hiddo J. L. Heerspink et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes
George L. Bakris et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
V. Perkovic et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial
Hertzel C. Gerstein et al.
LANCET (2019)
Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial
George L. Bakris et al.
AMERICAN JOURNAL OF NEPHROLOGY (2019)
Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial
Luis M. Ruilope et al.
AMERICAN JOURNAL OF NEPHROLOGY (2019)
Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial
Katherine R. Tuttle et al.
LANCET DIABETES & ENDOCRINOLOGY (2018)
The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study
William G. Herrington et al.
CLINICAL KIDNEY JOURNAL (2018)
SGLT2 inhibitors-induced electrolyte abnormalities: An analysis of the associated mechanisms
T. D. Filippatos et al.
DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS (2018)
Liraglutide and Renal Outcomes in Type 2 Diabetes
Johannes F. E. Mann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial
David Z. I. Cherney et al.
LANCET DIABETES & ENDOCRINOLOGY (2017)
Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications
Hiddo J. L. Heerspink et al.
CIRCULATION (2016)
Understanding CKD among patients with T2DM: prevalence, temporal trends, and treatment-patterns-NHANES 2007-2012
Bingcao Wu et al.
BMJ OPEN DIABETES RESEARCH & CARE (2016)
Finerenone, a Novel Selective Nonsteroidal Mineralocorticoid Receptor Antagonist Protects From Rat Cardiorenal Injury
Peter Kolkhof et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2014)
Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial
Bertram Pitt et al.
EUROPEAN HEART JOURNAL (2013)
Share Paper
